TABLE 6.

Hazard ratios (HR) for progression-free survival in the population with a favorable prognosis.

		Intervention [HR (95% CI)]
		CAB + NIV	AXY + PEM	LEN + PEM	SUN
Comparator	CAB + NIV		1.08 (0.56; 1.65)	0.59 (0.29; 0.94)	1.40 (0.84; 2.00)
	AXY + PEM	0.99 (0.52; 1.52)		0.56 (0.30; 0.85)	1.33 (0.94; 1.74)
	LEN + PEM	1.85 (0.91; 2.98)	1.91 (1.03; 2.90)		2.49 (1.59; 3.53)
	SUN	0.74 (0.45; 1.07)	0.77 (0.55; 1.01)	0.42 (0.27; 0.59)

The values in each cell represent the relative treatment effect for the intervention on the top when compared to the intervention on the left. Green suggests a relative treatment benefit (light green a nonsignificant benefit, and dark green a significant benefit). Red suggests a relative treatment harm (light red a nonsignificant harm, and dark red a significant harm).AXY, axitinib; CAB, cabozantinib; IPI, ipilimumab; LEN, lenvatinib; NIV, nivolumab; PEM, pembrolizumab; SUN, sunitinib